Taysha Q2 2026 net loss $46.6M; TSHA-102 pivotal dosing complete, $230M raised

Taysha Gene Therapies, Inc.

Net loss $46.6M ($0.13/share) vs $26.9M ($0.09) in Q2 2025; R&D expenses $38.6M vs $20.1M.
Completed dosing in REVEAL pivotal (N=17) and ASPIRE (N=4) trials for TSHA-102 in Rett syndrome; topline interim data expected 1H 2027.
TSHA-102 generally well tolerated with no severe treatment-related SAEs or DLTs across 33 patients as of Aug 2026 cutoff.
Completed $230M follow-on offering; cash and equivalents $455.4M as of June 30, 2026, runway into 2H 2028.
Expanded Catalent partnership for commercial manufacturing; appointed Mike Johannesen as Chief Legal Officer in June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.